About Aignostics
Aignostics is a company based in Berlin (Germany) founded in 2018 by Frederick Klauschen, Maximilian Alber, Viktor Matyas, and Klaus-Robert Muller. Aignostics has raised $53.89 million across 3 funding rounds from investors including Mayo Clinic, Athos and High-Tech Gründerfonds. The company has 25 employees as of December 31, 2021. Aignostics offers products and services including Foundation Models, Atlas H&E-TME, Target & Biomarker Discovery, Translational Research, and Digital Diagnostics. Aignostics operates in a competitive market with competitors including PathAI, Deepcell, Pictor Labs, Neko Health and Ovizio, among others.
- Headquarter Berlin, Germany
- Employees 25 as on 31 Dec, 2021
- Founders Frederick Klauschen, Maximilian Alber, Viktor Matyas, Klaus-Robert Muller
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Aignostics, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$53.89 M (USD)
in 3 rounds
-
Latest Funding Round
$34 M (USD), Series B
Oct 29, 2024
-
Investors
Mayo Clinic
& 8 more
-
Employee Count
25
as on Dec 31, 2021
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Aignostics
Aignostics offers a comprehensive portfolio of products and services, including Foundation Models, Atlas H&E-TME, Target & Biomarker Discovery, Translational Research, and Digital Diagnostics.
AI tools for generating embeddings in pathology workflows.
Application for comprehensive tumor microenvironment analysis.
Service to identify drug targets using multimodal datasets.
Service for measuring biomarkers across data modalities.
Tools to refine models for real-world clinical applications.
People of Aignostics
Unlock access to complete
Funding Insights of Aignostics
Aignostics has successfully raised a total of $53.89M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $34 million completed in October 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Aignostics
Aignostics has secured backing from 9 investors, including institutional and venture fund investors. Prominent investors backing the company include Mayo Clinic, Athos and High-Tech Gründerfonds.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early-stage investments are made in high-tech startups by HTGF.
|
Locked | Locked | Locked | |
|
Healthcare investments are targeted by Boehringer Ingelheim Venture Fund.
|
Locked | Locked | Locked | |
|
Early-stage investments are provided for life science and healthcare innovations.
|
Locked | Locked | Locked |
Investor details for Aignostics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Aignostics
Investment portfolio details for Aignostics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Aignostics
Detailed financials for Aignostics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Aignostics Comparisons
Peer comparison for Aignostics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Aignostics
Aignostics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as PathAI, Deepcell, Pictor Labs, Neko Health and Ovizio, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Provider of AI-based solutions for clinical diagnosis of cancer and other diseases
|
|
| Locked | Locked | Locked |
AI-powered single cell classification and isolation technology for clinical research
|
|
| Locked | Locked | Locked |
AI-based tools for pathological image analysis are provided to labs.
|
|
| Locked | Locked | Locked |
Platform offering solutions for preventive health scans
|
|
| Locked | Locked | Locked |
Imaging systems and AI software for microscopes are developed.
|
Detailed competitors of Aignostics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Aignostics
Complete news archive for Aignostics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Aignostics
Aignostics was founded in 2018 and raised its 1st funding round 2 years after it was founded.
Aignostics is headquartered in Berlin, Germany. It is registered at Berlin, Berlin, Germany.
Aignostics is a funded company, having raised a total of $53.89M across 3 funding rounds to date.
As of Dec 31, 2021, the latest employee count at Aignostics is 25.
Aignostics was founded in 2018 in Berlin, Germany, as a provider of AI-based software for pathology diagnostics. Patented technology is utilized to reverse-engineer AI models, enabling explainable results through heatmaps and image overlays. The software supports diagnostic processes in healthcare and extends to drug research, where microscopic visual estimations are analyzed and quantified. Operations focus on the healthcare and biotechnology sectors.
Aignostics's top competitors include Pictor Labs, PathAI and Neko Health.
Aignostics offers Foundation Models, Atlas H&E-TME, Target & Biomarker Discovery, Translational Research, and Digital Diagnostics.
Aignostics has 9 investors. Key investors include Mayo Clinic, Athos, High-Tech Gründerfonds, Wellington Partners, and Boehringer Ingelheim Venture Fund.